No appointments have yet been booked for Sue Barnden. She is at the centre all day on Thursday 26th September, and you can book a 45 mins slot. This is the first time she has been twice in one year, I do hope we can make her visit worthwhile. Please contact the centre for appointments.
Posts By: Karen Jones
Research request from Kings College London
Source Kings College London: “I am a third-year psychology student at King’s College London, currently assisting a PhD student, Jowinn Chew (cc’d in this email), on her research supervised by Dr Colette Hirsch and Prof Rona Moss-Morris from the Health Psychology Department. The research is focusing on identifying the cognitive mechanisms which underpin and maintain… Read more »
Early MS scans ‘can predict long-term prognosis’
Source BBC: Scans carried out when someone is first diagnosed with multiple sclerosis can predict their long-term prognosis, research has shown. Magnetic resonance imaging (MRI) scans are already a key part of the diagnosis and management of MS. But a 15-year study of people with clinically isolated syndrome (CIS), who can go on to develop MS,… Read more »
MS: Drugs trial hope for multiple sclerosis patients
Source BBC: Welsh patients are taking part in a drugs trial aimed at slowing late-stage multiple sclerosis progression. Experts are looking at how effective a drug is after a smaller study found it may slow down neuronal degeneration. Euryl James, of Llangennith, Gower, said she got involved as a breakthrough could be life-changing. A total… Read more »
EMA warns that Gilenya must not be taken during pregnancy.
Source MS Trust: The European Medicines Agency (EMA) has recommended that Gilenya (fingolimod) must not be taken by pregnant women or women of childbearing age who are not using effective contraception. A review of Gilenya and pregnancy was carried out by the EMA’s safety committee following reports which suggested that babies born to mothers taking Gilenya during pregnancy have… Read more »
100 club winners for July
100 club winners for July: 1st – Linda Tierney 2nd – Sue Doran 3rd – Steve Lewis Sharing a prize fund of: £77.50 You got to be in it to win it!! Speak to Sue for an application form, only £5 a month!
Phase 1 Trial of T20K, Plant Protein-derived Therapy for MS, Doses 1st Group of Healthy Men
Source Multiple Sclerosis News Today: A first group of healthy volunteers in a Phase 1 trial assessing the safety and tolerability of T20K, Cyxone‘s plant protein-derived candidate for the treatment of multiple sclerosis(MS), has been dosed in a study taking place in The Netherlands, the company announced. T20K is an investigational prophylactic (preventive) therapy, possibly intended for all MS… Read more »
Phase 3 Trial of Ibudilast Planned for SPMS Patients with Inactive Disease, MediciNova Says
Source Medical News Toady: A Phase 3 trial is planned to confirm the safety and efficacy of oral ibudilast (MN-166) in treating people with secondary progressive multiple sclerosis (SPMS) without relapses or those whose disease is not active, MediciNova announced. Data from this single Phase 3 study may be used to request marketing approval for ibudilast with the U.S. Food and Drug… Read more »
Scientists have discovered that a specific brain cell known as a ‘projection neuron’ has a central role to play in the brain changes seen in multiple sclerosis (MS).
Source Science Daily: The research shows that projection neurons are damaged by the body’s own immune cells and that this damage could underpin the brain shrinkage and cognitive changes associated with MS. These new findings provide a platform for specific new MS therapies that target damaged brain cells to be developed. Scientists have discovered that… Read more »
Scientists Identify Differences Between Relapsing/Remitting and Progressive Multiple Sclerosis
Source BioSpace: Multiple sclerosis (MS) is an often-disabling disease of the central nervous system caused by damage to the myelin coating around the nerves. The disease is quite variable but falls into two broad types, relapsing-remitting MS (RRMS), in which patients often go into clinical remission, and progression MS, which does not have remission periods, but… Read more »
